PD-1 and PD-L1 Inhibitors Market
完整報告名稱與涵蓋範圍
PD-1 and PD-L1 Inhibitors Market Size, Share & Trends Analysis Report By Drug Type (Atezolizumab, Avelumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab, Sintilimab, and Others), By Disease Type, Region And Segment Forecasts, 2025-2034
報告摘要
The worldwide PD-1 and PD-L1 Inhibitors Market stood at USD 48.7 Billion in 2024, and is expected to reach USD 166.9 Billion by 2034, recording a CAGR of 13.2% from 2025 through 2034.
The PD-1 and PD-L1 Inhibitors sector involves key industry insights & findings from the report:
Rising cancer patients, sophisticated healthcare systems, and substantial healthcare expenditures propel the market. This domain has witnessed considerable transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is fueled by growing healthcare spending, technological evolution, and the growing focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region expected to deliver the strongest growth trajectory through the forecast period, fueled by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PD-1 and PD-L1 Inhibitors Market Snapshot
Chapter 4. Global PD-1 and PD-L1 Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter's Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Key Trends in the Market
Chapter 5. Market Segmentation 1: Drugs Estimates & Trend Analysis
5.1. Drugs Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drugs:
5.2.1. Pembrolizumab
5.2.2. Nivolumab
5.2.3. Atezolizumab
5.2.4. Durvalumab
5.2.5. Avelumab
5.2.6. Cemiplimab
5.2.7. Sintilimab
5.2.8. Others
Chapter 6. PD-1 and PD-L1 Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis
6.1. Indication Analysis & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Melanoma
6.2.2. NSCLC
6.2.3. Renal cell carcinoma
6.2.4. Urothelial bladder cancer
6.2.5. Hodgkins Lymphoma
6.2.6. Merkel cell carcinoma
6.2.7. Colorectal cancer
6.2.8. Others
Chapter 7. PD-1 and PD-L1 Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Drugs, 2021-2034
7.1.2. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Indication, 2021-2034
7.1.3. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) estimates and forecasts by Country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034
7.2.2. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034
7.2.3. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034
7.3.2. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034
7.3.3. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drugs, 2021-2034
7.4.2. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Indication, 2021-2034
7.4.3. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Country, 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. MEA
7.5.1. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by Drug, 2021-2034
7.5.2. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Billion) by country, 2021-2034
7.5.2.1. South Africa
7.5.2.2. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major M &A /Research Institutes Partnerships, Alliances, and Agreements
8.2. Funding Activities
8.3. Company Profiles
8.3.1. Merck Co.
8.3.2. Bristol-Myers Squibb
8.3.3. Roche
8.3.4. AstraZeneca
8.3.5. Pfizer
8.3.6. Jiangsu HengRui Medicine
8.3.7. Regeneron Pharmaceuticals
8.3.8. ONO PHARMACEUTICAL CO., LTD.
8.3.9. Eli Lilly and Company
8.3.10. Innovent Biologics, Inc.
8.3.11. BeiGene
8.3.12. Junshi Biosciences Co.
8.3.13. Biocad
8.3.14. 4D pharma plc.
8.3.15. Agenus Inc.
8.3.16. Calithera.
8.3.17. Curis, Inc.
8.3.18. Constellation Pharmaceuticals, Inc.
8.3.19. Compass Therapeutics
8.3.20. Corvus Pharmaceuticals
8.3.21. CytomX Therapeutics, Inc.
8.3.22. eFFECTOR Therapeutics, Inc.
8.3.23. Jounce Therapeutics, Inc.
8.3.24. MacroGenics, Inc.
8.3.25. Mirati Therapeutics, Inc.
8.3.26. Moderna, Inc.
8.3.27. MultiVir, Inc.
8.3.28. NovoCure Ltd.
8.3.29. NeoImmuneTech, Inc.
8.3.30. Syndax Pharmaceuticals
8.3.31. PrimeVax Immuno-Oncology Inc.
8.3.32. Incyte Corporation
8.3.33. Trillium Therapeutics Inc.
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們